Chiron’s Proleukin (IL-2)
Executive Summary
Sales of the interleukin-2 product are expected to be "closer to $50 mil. in 1993," about double 1992 sales of $25 mil. that came primarily from Europe, Chiron's Ed Penhoet tells Alex. Brown conference. Proleukin was approved in the U.S. May 5 for the treatment of metastatic renal cell carcinoma.